Martin Reck

Working on medicine

[Stephen V Liu, MD @StephenVLiu]

Dr. @MartinReck2 presents data on 1L PF-08634404 (VEGF-PD1 bispecific) in PD-L1 positive NSCLC at #ASCO26 (SSGJ-707-NSCLC-II-01 study in China). At 10mg/kg, RR 68%, DCR 97%, DOR 18m. Median PFS 12.4m with 12m rate 56%. Encouraging early efficacy signals.

[OncoAlert @OncoAlert]

The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC .
A snapshot of what will shape LUNG oncology at #ASCO26 👇

🔹 HARMONI-6 — Ivonescimab + chemo vs tislelizumab + chemo in sqNSCLC (OS, Ph3)
🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET+ NSCLC (EFS, Ph3)
🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3)
🔹 OPTITROP-LUNGO5 — Sac-TMT + pembrolizumab in PD-L1+ NSCLC (Ph3)
🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC
🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK+ NSCLC
🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK+ NSCLC
🔹 ACCELERET-LUNG — 1L pralsetinib in RET+ NSCLC
🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC
🔹 Concurrent CRT + durvalumab in ES-SCLC (Phase III)

Leads
@HHorinouchi
@UOzkerim
@WeOncologists

Senior Faculty
@GlopesMd
@StephenVLiu
@peters_solange
@CharuAggarwalMD
@MartinReck2
@christine_lovly

Participating AF
@DrMirallas

Pinging faculty
@bmassutis @UmbertoMalapel1
@jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo
@Latinamd @JulienMazieres @TerriConneran @BRicciutiMD

[Martin Reck @MartinReck2]

RT @g_mountzios: An exciting morning session here in @myESMO advanced course in early stage #NSCLC with a “deep dive” into :

➡️ Environmen…

[International Lung Cancer Summit @LungSummit]

Are we seeing a shift in post-TKI treatment for EGFR-mutant NSCLC?

In our Year in Review roundtable, @MartinReck2 discusses the growing role of TROP2-directed ADCs in lung cancer, including data from late-line and earlier-line studies presented for patients progressing after EGFR-TKIs.

The discussion highlights improvements in response and PFS, and the broader question of how TROP2 ADCs may reshape treatment sequencing.

Watch the full discussion with @peters_solange and @charlesrudin ⬇️
https://t.co/Y105J3ZuKH

[Noemi Reguart @NReguart]

On behalf of the ESMO Nominations Committee—@MartinReck2 @hoperugo , Ulrik Lassen and Nicoletta Colombo—we warmly invite colleagues to nominate those who shine, inspire, lead, and advance excellence in oncology 🌟. Let’s take part and help recognize them together! 🗓️Closes 10 May

[Herbert Loong, MBBS, FASCO @herbloong]

Lots of work to be done today as #trackchairs under leadership of the congress chairs @MLJohnsonMD2 and @tompowles1 of @myESMO #ESMO27 get together to confirm the educational sessions for the meeting - more than 1.5 years in advance.

24+ tracks at upcoming #ESMO27 in Barcelona. Stay tuned!

@FAndreMD @curijoey @LizzySmyth1 @GPentheroudakis @AACRPres @MartinReck2 @ca_chung @NReguart @hoperugo #MakotoTahara @TeresaSAmaral and many others

[OncoDaily @oncodaily]

@g_mountzios @MartinReck2 @JordiRemon @HendriksLizza @JessicaMenis @RobertoFerrara_ @DrJNaidoo @NReguart @HLinardou @NarjustFlorezMD @JhanelleGray We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/4fFoeG0GWD

[Xiuning Le MD PhD @LeXiuning]

😊 🩷 Nice to see friends and colleagues in the #lungcancer community from different continents at #ELCC26. @caliraf @Alfdoc2 @HHorinouchi @MartinReck2 @Tony_Calles @DoctorJSpicer @fred_hirsch @bensolomon1 @NReguart @BalazsHalmosMD @BrendonStilesMD @mollylisc @karenkellymd @ThomasW35874311 @NadalErnest @DrSanjayPopat 😊 🩷 Safe travels ✈️
💐💐💐Grateful for the wonderful organization between @IASLC and @esmo for an impactful and fun #ELCC26.

[Giannis Mountzios @g_mountzios]

Back home from an amazing #ELCC26, I keep reflecting on the true value of scientific meetings:
The best science and education comes only among people who are unite by friendship, mutual respect and a common vision: to improve the care of our patients with lung cancer
See you all in #ELCC27!
@myESMO
@IASLC

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ELCC26 @myESMO @IASLC 🇩🇰
🔥Mini Oral session 2
☑️KEYNOTE-671: 5 years F/U in non-pCR subgroup
🎯EFS HR 0.69, 5-y rate 42.9% vs. 25.2%, OS immature
🎙️ @MartinReck2
🎙️Chair: Dr. Kersti Oselin @MARIANOPROVENCI
📍NCT03425643
@OncoAlert @Larvol #LCSM

[Giannis Mountzios @g_mountzios]

#ELCC26 @MartinReck2 on KN671 exploratory analysis of patients without pCR

5-year EFS 43% vs 25% , HR =0,69, 95%CI 0.57-0.83)

[Thoracic Oncology Frontier @IONCOLOGYLung]

#ELCC26 Day3 Mini Oral
@MartinReck2 presented "Exploratory Analysis of Participants Without Pathological Complete Response
(pCR) in the KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) in Early-Stage #NSCLC After 5 Years of Follow-Up"
@IASLC @myESMO

[Kai @bmassutis]

Issue of impact and value Postop immunotherapy in perioperative strategy in NSCLC start to be analyzed @MartinReck2 at #ELCC2026 @OncoAlert

[Jarushka Naidoo @DrJNaidoo]

T-2 days until #ELCC26 in Copenhagen🇩🇰

Join myself, @JordiRemon #CaicunZhou & #SarahPilotto to learn about all things KRAS on day 1, led by @MartinReck2

@myESMO #ESMOAmbassadors #ELCC26 @KRASKickers @OncoAlert @CancerCentreIre @cancertrials_ie #LCSM

[d.planchard @dplanchard]

Always a privilege to listen to one of the true pioneers of immunotherapy in thoracic oncology @MartinReck2 . Inspiring as ever ! @myESMO

[Balazs Halmos @BalazsHalmosMD]

I am starting to notice that after 20+ yrs of oncology some of my skills are starting to be as good as that of a top Ortho surgeon!

[The Annals of Thoracic Surgery @annalsthorsurg]

#GeneralThoracic #CME article from Liberman et al on Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671: https://t.co/7ciW1IIzSk
@JonesDavid2013 @HwakeleeMD @BalazsHalmosMD @NadalErnest @MartinReck2 @DoctorJSpicer

[Giannis Mountzios @g_mountzios]

Are you interested for a deep-dive in early stage #NSCLC including perioperative IO/targeted, ADCs and future trial design?

Don't miss the @myESMO advanced course in #Athens on 23-24th April chaired by @peters_solange , @ElinardouHelena and myself
Register: 👉https://t.co/DRzqXkm9c4
Deadline: 18 March 2026

@OncoAlert #some #LCSM

[International Lung Cancer Summit @LungSummit]

A new therapeutic opportunity is emerging in MTAP-deleted NSCLC using PRMT5 inhibitors.

During our Year in Review roundtable with @peters_solange, @MartinReck2 and @charlesrudin, we learned how this new class of drugs may target 10% to 30% of all NSCLC cases. These compounds are also being developed in other solid tumors and are now moving into frontline strategies with chemo and potentially IO.

Watch the full roundtable here ⬇️
https://t.co/Xz3CofsSTS

[Martin Reck @MartinReck2]

Just out! Delighted to share some work on (IO) refractory Lung Cancer. Thank you for a fantastic cooped! Feasibility and safety of nintedanib in combination with nivolumab in ... https://t.co/nKBE7Y2nPf #LCSM